丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

European shares slipped on Friday (Sep 20) after a rally in the previous session spurred by the US Federal Reserve’s outsized ...

美东时间周五，三大股指涨跌不一，道指再创历史新高。在前一日大涨后，投资者权衡美联储下一步举措，并未继续大笔买入，此外，多家公司令人失望的财报也限制了涨幅。

美股市场： 美股收盘涨跌不一， 三大指数 周线两连涨， 道指续创收盘新高 。截止收盘， 道琼斯工业平均指数比前一交易日上涨38.17点，收于42063.36点，涨幅为0.09%； 标准普尔 500种股票指数 下跌 11.09点，收于5702.55点， ...

博时基金最新董事会成员变更公告显示，因博时基金管理有限公司第八届董事会任期届满，经公司股东会 2024 ...

This post was written by Luke Carberry Mogan. Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor ...